Kirsty (Insulin Aspart)

• Insulin aspart in Kirsty is a rapid‑acting insulin analog used in the management of diabetes mellitus.
• Type 1 diabetes mellitus: provides mealtime insulin to lower post‑prandial glucose levels.
• Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve target glycaemic control.
• Postprandial hyperglycemia: reduces post‑meal glucose excursions when administered before meals.

• Insulin aspart binds to the insulin receptor on muscle, adipose and hepatic cells, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling cascades that promote translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering circulating blood glucose levels rapidly after subcutaneous injection.

Insulin aspart may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypoglycemia: low blood glucose levels that may cause sweating, tremor, or confusion.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increase in body weight associated with improved glycaemic control.
• Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Severe hypoglycemia: prolonged low blood glucose leading to seizures or loss of consciousness.
• Hypokalemia: low serum potassium levels that may affect cardiac function.
• Acute insulin allergy: systemic allergic manifestations such as rash, urticaria, or angioedema.

When using insulin aspart, several precautions should be observed to ensure safe and effective therapy.

• Dose adjustment: tailor insulin dose based on blood glucose monitoring, diet, and activity level.
• Renal impairment: monitor closely as reduced clearance may increase risk of hypoglycemia.
• Pregnancy: use only if benefits outweigh risks; consult healthcare provider for individualized assessment.
• Concomitant medications: review other drugs that affect glucose levels, such as sulfonylureas or beta‑blockers.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulin aspart can interact with other medicines, altering its glucose‑lowering effect or increasing adverse risk.

Major Interactions (Avoid)

• Sulfonylureas: combined use may cause severe hypoglycemia.
• Beta‑blockers: may mask hypoglycemia symptoms.
• Corticosteroids: can reduce insulin effectiveness, requiring dose increase.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may potentiate hypoglycemic effect.
• Diuretics (thiazides): can affect potassium levels and glucose control.
• Oral contraceptives: may slightly increase insulin requirements.